UnitedHealthcare Community Plan

Clinical Pharmacy Program Guidelines for Tobramycin Inhalation

Program	Prior Authorization
Medication	Bethkis®, Kitabis™ Pak, TOBI™ Nebulizer Solution and TOBI® Podhaler™
Markets in Scope	California, Florida-CHIP, Hawaii, Maryland, Nevada, New Mexico, New York, New York EPP, Ohio, Rhode Island, Washington, New Jersey, Louisiana
Issue Date	9/2013
Pharmacy and Therapeutics Approval Date	2/2018
Effective Date	4/2018

1. Background:

Bethkis (tobramycin) is an inhaled aminoglycoside antibacterial indicated for the management of cystic fibrosis patients with *Pseudomonas aeruginosa*. Safety and efficacy have not been demonstrated in patients under the age of six years, patients with a forced expiratory volume in less than one second (FEV1) less than 40% or greater than 80% predicted, or patients colonized with *Burkholderia cepacia*. Bethkis is administered by inhalation using a hand-held PARI LC Plus® Reusable Nebulizer with a PARI Vios Air compressor. After 28 days of therapy, patients should stop Bethkis therapy for the next 28 days, and then resume therapy for the next 28 day on and 28 day off cycle.[3]

TOBI (tobramycin) is an antibacterial aminoglycoside indicated for the management of cystic fibrosis patients with *Pseudomonas aeruginosa*. Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV1) < 25% or > 75%, or patients colonized with *Burkholderia cepacia.*[1,2] TOBI Nebulizer Solution is specifically formulated for inhalation using the DeVilbiss® Pulmo-Aide® air compressor and PARI LC Plus® Reusable Nebulizer.[1] The contents of TOBI Podhaler capsules are only for oral inhalation and should only be used with the Podhaler device.[2] After 28 days of therapy, patients should stop TOBI therapy for the next 28 days, and then resume therapy for the next 28 day on and 28 day off cycle.[1,2]

Kitabis Pak (co-packaging of tobramycin inhalation solution and PARI LC Plus® Reusable Nebulizer) is an aminoglycoside antibacterial drug indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with *Pseudomonas aeruginosa*. Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with FEV1 <25% or >75% predicted, or patients colonized with *Burkholderia cepacia*. After 28 days of therapy, patients should stop Kitabis therapy for the next 28 days, and then resume therapy for the next 28 day on and 28 day off cycle.[4]

Members will be required to meet the coverage criteria below.

2. Coverage Criteria:

A. Bethkis

1. Authorization

a. **Bethkis** will be approved based on the following criteria:

(1) Diagnosis of cystic fibrosis (CF)

Authorization will be issued for 12 months

B. Non-Preferred Products

1. Initial Authorization

a. **Kitabis Pak, TOBI Nebulizer Solution, TOBI Podhaler, or tobramycin solution for inhalation** will be approved based on **all** of the following criteria:

(1) Diagnosis of cystic fibrosis (CF)

-AND-

(2) Lung infection with positive culture demonstrating *Pseudomonas aeruginosa* infection

-AND-

(3) History of failure, intolerance, or contraindication to Bethkis

Authorization will be issued for 12 months

2. Reauthorization

a. **Kitabis Pak, TOBI Nebulizer Solution, TOBI Podhaler, or tobramycin solution for inhalation** will be approved based on the following criterion:

(1) Documentation of positive clinical response to Kitabis Pak, TOBI Nebulizer Solution, TOBI Podhaler, or tobramycin solution for inhalation therapy

UnitedHealthcare Community Plan

Authorization will be issued for 12 months

3. References:

1. TOBI Inhalation Solution [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; October 2015.
2. TOBI Podhaler [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; October 2015.
3. Bethkis [package insert]. Woodstock, Illinois: Cornerstone Therapeutics Inc.; May 2017.
4. Kitabis Pak [package insert]. Woodstock, Illinois: Catalent Pharma Solutions, LLC; November 2014.
5. Tobramycin Inhalation Solution [package insert]. Sellersville, PA.: Teva Pharmaceuticals USA; October 2015.

Program	Prior Authorization
Change Control	
9/19/2013	New guideline
6/19/2014	Bethkis added to the PDL with prior authorization. Tobi Nebulizer deleted from PDL.
12/17/2015	Annual review, no change
11/2016	Updated non-preferred products section and added reauthorization criteria. Updated policy template.
2/2017	Annual review with no changes to coverage criteria.
9/2017	Removed lung infection with positive culture requirement and reauthorization criteria for Bethkis to allow for Dx to Rx implementation.
2/2018	Annual review. Updated references.